Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on December 29, 2020. The filing reports the closing of a registered direct offering of common stock.
Key Financial Metrics
- Offering Proceeds: The Company received gross proceeds of $6,500,000 from the sale of 14,444,444 shares of common stock.
- Cash Position: Following the offering, available cash, inclusive of net proceeds, is approximately $17.6 million.
- Shares Outstanding: Total common stock outstanding is 91,766,928 shares post-offering.
- Revenue, Profit, and Debt: The filing text does not provide specific values for revenue, profit, operating margins, or debt levels.
Material Changes
The primary material change reported is the increase in share count and cash liquidity resulting from the December 29, 2020, registered direct offering. No other material changes to financial performance or operations are detailed in this specific filing.
Outlook and Management Commentary
The filing references a press release (Exhibit 99.1) regarding the offering but does not contain specific forward-looking guidance, risk factors, or management commentary within the body of this 8-K text.
Investor Verification Checklist
- Verify the net proceeds calculation by reviewing the underwriting discounts and commissions in the full press release (Exhibit 99.1).
- Confirm the dilution impact of the 14,444,444 new shares on existing shareholders.
- Review the Company's most recent 10-Q or 10-K for detailed revenue, expense, and debt metrics not included in this 8-K.
- Assess the intended use of the $17.6 million cash balance as disclosed in the accompanying press release.